MarketCap
Facebook
X
Telegram
Curis Accounts Receivables | CRIS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.35 M | 2.79 M | 2.98 M | 3.22 M | 3.04 M | 3.24 M | 2.86 M | 3.07 M | 2.46 M | 2.11 M | 1.96 M | 1.48 M | 908 K | 42.1 K | 92.4 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 M | 42.1 K | 2.24 M |
Quarterly Accounts Receivables Curis
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.24 M | 2.75 M | 2.32 M | 3.35 M | 2.98 M | 2.55 M | 2.15 M | 2.79 M | 2.85 M | 2.39 M | 2.31 M | 2.98 M | 2.89 M | - | 2.06 M | 3.22 M | 2.96 M | 2.38 M | 2.18 M | 3.04 M | 3.04 M | 3.04 M | 3.04 M | 3.24 M | 3.24 M | 3.24 M | 3.24 M | 2.86 M | 2.86 M | 2.86 M | 2.86 M | 3.07 M | 3.07 M | 3.07 M | 3.07 M | 2.46 M | 2.46 M | 2.46 M | 2.46 M | 2.11 M | 2.11 M | 2.11 M | 2.11 M | 1.96 M | 1.96 M | 1.96 M | 1.96 M | 1.48 M | 1.48 M | 1.48 M | 1.48 M | 908 K | 908 K | 908 K | 908 K | 42.1 K | 42.1 K | 42.1 K | 42.1 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 M | 42.1 K | 2.29 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
47 M | $ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alkermes plc
ALKS
|
334 M | $ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
1.22 M | $ 3.31 | 1.22 % | $ 292 M | USA |
 |
Amgen
AMGN
|
9.57 B | $ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
127 M | $ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
742 M | $ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
12.6 B | $ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
33.8 M | $ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
23.7 M | $ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
281 M | $ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aptevo Therapeutics
APVO
|
5.22 M | $ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
5.56 M | $ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
71.8 M | $ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
25 K | $ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Arvinas
ARVN
|
1 M | $ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.82 M | $ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
974 K | $ 28.86 | 0.64 % | $ 324 M | USA |
 |
Atara Biotherapeutics
ATRA
|
1.25 M | $ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
1.83 M | $ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
41.5 M | $ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Axon Enterprise
AXON
|
18.1 M | $ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
107 M | $ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
2.04 M | $ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Biogen
BIIB
|
1.34 B | $ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
11.4 B | $ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
33 K | $ 12.11 | 0.08 % | $ 498 M | USA |